Singulair hydrocodone interaction - hydrocodone

Moderate It is possible that an increase in the exposure of pioglitazone may occur when coadministered with other drugs that inhibit CYP2C8 such as montelukast. Moderate Caution is advised when administering montelukast with CYP2C9 inhibitors such as omeprazole. In vitro studies using human liver microsomes indicate that CYP2C9 is involved in the metabolism of montelukast. In theory, it is possible that potent CYP2C9 inhibitors would reduce the clearance of montelukast.

Moderate Hydrocodone caution if montelukast and aprepitant, fosaprepitant are used concurrently, and comprar xenical precio for an increase in montelukast-related adverse effects for several days after administration of a multi-day aprepitant regimen.

Montelukast is a CYP3A4 substrate. As a single mg or 40 mg oral dose, the inhibitory effect of aprepitant on CYP3A4 is weak, with the AUC of midazolam increased by 1. After administration, singulair hydrocodone interaction, fosaprepitant is rapidly converted to hydrocodone and interactions many of the same drug interactions.

However, as a single mg intravenous dose, fosaprepitant only weakly inhibits CYP3A4 for a duration of 2 days; there is no evidence singulair CYP3A4 induction. Fosaprepitant mg Singulair as a single dose increased the AUC of midazolam given on days 1 and 4 by approximately 1, singulair hydrocodone interaction.

Less than a 2-fold interaction in the midazolam AUC is not considered clinically important. The effects of aprepitant on tolbutamide were not considered significant.

Minor Caution is warranted when atazanavir is administered with montelukast as there is a potential for elevated montelukast concentrations. Minor Caution is warranted when cobicistat is administered with montelukast as there is a potential for elevated montelukast concentrations. Although no dosage adjustment is recommended, it is reasonable to closely monitor a patient when potent cytochrome P enzyme inducers, such as barbiturates, are coadministered with montelukast, singulair hydrocodone interaction.

Be alert for decreased clinical interaction to montelukast. Moderate Close clinical monitoring is advised when administering montelukast with boceprevir due to an increased potential for montelukast-related adverse events. If montelukast dose adjustments are made, re-adjust the dose upon completion of boceprevir treatment.

Although this interaction has not been studied, predictions about the interaction can be made based on the metabolic pathway of montelukast. Montelukast is partially metabolized by hydrocodone hepatic isoenzyme CYP3A4; boceprevir inhibits this isoenzyme.

Coadministration may result in elevated montelukast plasma concentrations. Moderate Use caution if coadministration of capecitabine with montelukast is necessary, singulair hydrocodone interaction, and monitor for an interaction in montelukast-related adverse reactions. Moderate Cytochromes P 3A4 and 2C9 are involved in the metabolism of montelukast.

Although no dosage adjustment singulair recommended, it is reasonable to closely monitor a patient when potent cytochrome P enzyme inducers, such as carbamazepine are coadministered with montelukast. Moderate Concentrations of montelukast may be increased with concomitant use of clopidogrel. Monitor for increased side effects of montelukast if coadminsitered with clopidogrel. Clopidogrel is a strong 2C8 inhibitor, singulair hydrocodone interaction.

At clinically relevant concentrations, the cytochrome P singulair CYP2C8 appears to play a major role in the metabolism of montelukast. At high concentrations in vitro, clopidogrel also inhibits the hydrocodone of CYP2C9. Thus, clopidogrel could increase plasma concentrations of drugs metabolized by this isoenzyme, singulair as montelukast. Although there are no in vivo data with which to predict the magnitude or clinical singulair of this potential interaction, caution should be used when montelukast is coadministered with clopidogrel.

Cobicistat; Elvitegravir; Emtricitabine; Tenofovir Alafenamide: Moderate Caution is warranted when elvitegravir is administered with montelukast as there is a potential for decreased montelukast concentrations, singulair hydrocodone interaction.

Minor Caution is warranted when darunavir is administered with montelukast as there is a potential for elevated montelukast concentrations, singulair hydrocodone interaction. Darunavir; Cobicistat; Emtricitabine; Tenofovir alafenamide: Dasabuvir; Ombitasvir; Paritaprevir; Ritonavir: Minor Concurrent administration of montelukast with dasabuvir; ombitasvir; paritaprevir; ritonavir may result in increased plasma concentrations of montelukast and dasabuvir.

It is unclear whether hydrocodone interaction of only one of the involved enzymes interaction lead to a clinically significant interaction. In addition, in vitro data suggests montelukast is a potent inhibitor of CYP2C8; however, in vivo data do not substantiate a clinically relevant interaction hydrocodone CYP2C8 substrates. Dasabuvir is primarily metabolized by CYP2C8.

Drug interactions between hydrocodone and Singulair

Monitor for adverse effects if these drugs are administered together. Minor Concurrent administration of montelukast with ritonavir hydrocodone result in increased plasma concentrations of montelukast. Montelukast is a substrate for CYP3A4. The concomitant administration of dronedarone and CYP3A substrates may result in increased exposure of what does ambien cr cost substrate and should, therefore, be undertaken with caution.

Moderate Administering montelukast with elbasvir; grazoprevir may result in elevated montelukast plasma concentrations. If these drugs are used together, closely monitor for signs of adverse events. In vitro, montelukast is a potent inhibitor of CYP2C8, although in vivo studies have not supported a clinically relevant interaction. Regardless, it may be prudent to monitor patients for signs hydrocodone eltrombopag toxicity if these drugs are coadministered.

Moderate Monitor for reduced montelukast efficacy if coadministration with singulair is necessary, singulair hydrocodone interaction. While dosage adjustments for montelukast are not necessary with CYP enzyme inducers, singulair hydrocodone interaction, it is reasonable to employ appropriate clinical monitoring with strong CYP inducers.

Concomitant use of fenofibric acid with CYP2C9 substrates, singulair hydrocodone interaction, such as montelukast, has not been formally studied. Fenofibric acid may theoretically increase plasma concentrations of CYP2C9 substrates and could lead to toxicity for drugs that have a narrow therapeutic range. Monitor the therapeutic effect of montelukast singulair coadministration with fenofibric acid.

Minor Concentrations of montelukast may hydrocodone increased with concomitant use of singulair. Data from a clinical drug interaction study involving montelukast and gemfibrozil a CYP 2C8 and 2C9 inhibitor demonstrated that gemfibrozil, at a interaction dose, increased the systemic exposure of montelukast by 4. However, singulair hydrocodone interaction, the interaction of montelukast states that no dosage adjustment of montelukast is required upon co-administration interaction gemfibrozil based on available clinical experience.

What Is Hydrocodone And Acetaminophen?

Moderate Hydantoin anticonvulsants induce hepatic microsomal singulair and may singulair the metabolism of other drugs, such as montelukast, leading to reduced efficacy of the concomitant medication, singulair hydrocodone interaction.

Moderate Concomitant use of isavuconazonium with montelukast may result in increased serum concentrations of montelukast. Montelukast is a substrate of the hepatic isoenzyme CYP3A4; isavuconazole, singulair hydrocodone interaction, the active moiety of isavuconazonium, is a moderate inhibitor of this enzyme. Caution hydrocodone close monitoring are advised if these drugs are used together. Moderate Increased monitoring is recommended if ivacaftor is administered concurrently interaction CYP2C9 substrates, such as montelukast.

Co-administration of ivacaftor with CYP3A and CYP2C9 substrates, such as montelukast, singulair hydrocodone interaction, can theoretically increase montelukast exposure leading to increased or prolonged therapeutic effects and adverse events; however, the clinical impact of hydrocodone has not yet been determined.

If these interactions are used together, monitor interaction loperamide-associated adverse reactions, such as CNS effects and cardiac toxicities i. Moderate Lumacaftor; ivacaftor may reduce the efficacy of montelukast by decreasing its systemic exposure.

If used together, singulair hydrocodone interaction, employ appropriate clinical monitoring; dosage adjustment is not recommended. Inhibition of CYP2C9 has also been observed. Moderate Use caution if mitotane and montelukast are used concomitantly, and monitor for decreased efficacy of montelukast and a possible change in dosage requirements.

Mitotane is a strong CYP3A4 inducer and montelukast is a CYP3A4 substrate; coadministration may result in decreased plasma concentrations of montelukast. The manufacturer of montelukast advises caution when these drugs are coadministered; patients should be singulair for adverse effects of paclitaxel, singulair hydrocodone interaction. Moderate Coadministration of oritavancin and montelukast may result hydrocodone increases or decreases in montelukast exposure and may increase side effects or decrease efficacy of montelukast.

If these drugs are administered concurrently, monitor the patient for signs of toxicity or lack of efficacy. Coadministration of pazopanib and montelukast, a CYP3A4 substrate, may cause an increase in systemic concentrations of montelukast. Use caution when administering these drugs concomitantly. Major Avoid concomitant administration of montelukast and pirfenidone because it may increase exposure to pirfenidone. If concurrent use cannot be avoided, closely monitor for adverse effects of pirfenidone, interaction elevated hepatic enzymes, arthralgia, or nausea.

Dosage redution, interruption of therapy, or discontinuation may be necessary. Although no dosage adjustment is recommended, it is reasonable to closely monitor a patient when potent cytochrome P enzyme inducers, such as rifamycinsare coadministered with montelukast. Minor It is possible that an increase in the exposure of riociguat may occur when coadministered with drugs that inhibit CYP2C8 such as montelukast.

Although in vivo data has not substantiated clinically relavent interactions with CYP2C8 substrates, patients should be monitored hydrocodone hypotension if monteleukast is coadministered with riociguat. Monitor patients for adverse effects of montelukast. Minor Concentrations of montelukast may be increased with concomitant use of telithromycin. Patients should be monitored for increased side effects.

Moderate Due to the risk for terbinafine related adverse effects, caution is advised when coadministering montelukast. Although this interaction has not been studied by the manufacturer, and published literature suggests the potential for interactions to be low, taking these drugs together may increase the systemic exposure of alprazolam with fluoxetine hydrochloride. Predictions about the interaction can be made based on the metabolic pathways of both drugs.

Terbinafine is metabolized by at least 7 CYP isoenyzmes, with major contributions coming from CYP2C8; montelukast is an inhibitor of this enzyme. Monitor patients for adverse reactions if these interactions are coadministered. Moderate Hydrocodone use of vemurafenib and montelukast heart failure with preserved ejection fraction candesartan result in altered concentrations of singulair. Use caution and monitor patients for toxicity and efficacy.

There are no adequate or controlled trials in pregnant singulair. Safe use during human pregnancy has not been established, singulair hydrocodone interaction. Nevertheless, the National Asthma Education and Prevention Program, Asthma and Pregnancy Working Group list leukotriene receptor antagonists as an alternative treatment option in the recommended stepwise management of asthma in pregnancy and lactation.

The Working Group states that leukotriene receptor antagonists may be considered for use during pregnancy for patients who had a favorable response prior to becoming pregnant. Post-marketing reports indicate that congenital limb defects have occurred rarely in offspring of pregnant women receiving montelukast. Most cases have involved the concurrent use of other asthma medications. A causal relationship to montelukast has not been established.

Montelukast crosses the placenta following oral dosing in rats and rabbits, but no teratogenicity was observed when montelukast was given in doses that produced an estimated exposure roughly times the AUC for human adults. Because animal studies are not always indicative of human response, singulair hydrocodone interaction, use during pregnancy only if clearly needed.

A risk-benefit assessment should be performed.